Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.12 USD

96.12
370,120

+0.08 (0.08%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Universal Health Services (UHS) Hits 52-Week Low on Dull Q3

Universal Health (UHS) stock suffers on soft third-quarter results and a tepid outlook.

    Amedisys (AMED) Q3 Earnings Beat, Revenues Miss Estimates

    At Hospice division, Amedisys (AMED) registered strong growth across all segments in Q3.

      Envision Healthcare Hits 52-Week Low on Q3 Miss, Grim View (Revised)

      Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.

        Envision Healthcare Hits 52-Week Low on Q3 Loss, Grim View

        Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.

          What's in the Cards for DaVita (DVA) Stock in Q3 Earnings?

          DaVita's (DVA) ongoing cost inflation might weigh on its margins in Q3. However, the Kidney Care business raises hope with steady investments in capital-efficient technologies.

            What's in Store for Madrigal (MDGL) This Earnings Season?

            Madrigal (MDGL) expects data readout for its lead candidate MGL-3196 on its third-quarter earnings call.

              What's in Store for Catalyst (CPRX) This Earnings Season?

              Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.

                Amedisys' Arm Buys Intercity Home Care, Boosts U.S. Base

                Amedisys' (AMED) encouraging efforts put the Personal Care business on growth track. This segment lives up to a strong performance with the integration of several recent tuck-in acquisitions.

                  Envision Healthcare Continues to Expand Physician Services

                  Envision Healthcare's (EVHC) numerous acquisitions and management changes are aimed at growing its physician services segment.

                    Here's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now

                    The market is upbeat about Mazor Robotics' (MZOR) recent CE Mark approval for Mazor X Surgical Assurance platform.

                      STERIS (STE) Rides on Organic Growth, Stiff Contest a Threat

                      STERIS' (STE) consistent strong organic all-segment growth performance impresses investors. Additionally, growth in free cash flow reserve denotes the company's solid cash position.

                        Here's Why You Should Invest in Orthofix International Now

                        Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation.

                          Can AngioDynamics (ANGO) Spring a Surprise in Q1 Earnings?

                          AngioDynamics (ANGO) is set to report first-quarter fiscal 2018 (ending Aug 31, 2017) results on Sep 28.

                            Omnicell (OMCL) Gains on Product Launches, Global Expansion

                            The market is upbeat about Omnicell's (OMCL) recently-launched XT Series Automated Supply Dispensing Cabinet. The company is also expanding its footprint globally.

                              Align Technology (ALGN) Prospects Bright, Competition Rife

                              Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.

                                PetMed Express Optimistic on New Orders Amid Stiff Rivalry

                                PetMed is striving to implement several strategies to revitalize its top line. Yet a highly competitive market poses threats.

                                  Anthem to Boost Medicare in Florida With HealthSun Buyout

                                  Anthem's (ANTM) inorganic growth continues to boost its top line. It strategically deploys capital in acquisitions to position its Medicare business for further growth.

                                    Medtronic Advances in Pain Therapy With U.S. Intellis Launch

                                    We look forward to a solid customer adoption of Medtronic's (MDT) Intellis platform, considering the vast and expanding market for chronic pain management.

                                      Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

                                      The market is upbeat about Abbott (ABT) acquiring the national reimbursement for FreeStyleLibre glucose monitoring system in the United Kingdom. Several product launches also add value.

                                        Amedisys or Chemed: Which is a Better Investment Choice?

                                        After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).

                                          Why Should Investors Add Amedisys (AMED) to Their Portfolio?

                                          Amedisys (AMED) rides high on solid prospects with new opportunities within home health and hospice services segments.

                                            Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

                                            IDEXX Laboratories (IDXX) continues to boost investor's confidence with strong companion animal business along with balanced growth across all segments.

                                              Why is Edwards Lifesciences (EW) a Strong Buy Stock Now?

                                              Several recent FDA product-approvals boost investors' trust in Edwards Lifesciences' (EW) stock.

                                                Here's Why You Should Add Chemed (CHE) to Your Portfolio

                                                Chemed (CHE) bolsters investor's confidence with continued strength in Roto-Rooter business.

                                                  Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now

                                                  BioTelemetry's (BEAT) consistent efforts in product innovation through research and development buoy optimism. Also, the recent acquisition instills confidence in investors.